RTP Mobile Logo
Select Publications

Ascierto PA et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. ASCO 2017;Abstract 9520.

Blank CU et al. First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. ASCO 2020;Abstract 10002.

Cristescu R et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 2018;362(6411):eaar3593. Abstract

Diab A et al. NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. ASCO 2018;Abstract 3006.

Dummer R et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018;19(10):1315-27. Abstract

Eggermont AM et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up. ASCO 2020;Abstract 10000.

Gogas H et al. Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma. ASCO 2020;Abstract 10012.

Hauschild A et al. Long-term benefit of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD. ASCO 2020;Abstract 10001.

Heinzerling L et al. Tolerability of BRAF/MEK inhibitor combinations: Adverse event evaluation and management. ESMO Open 2019;4(3):e000491. Abstract

Hodi FS et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018;19:1480–92. Abstract

Johnson DB et al. Sequencing treatment in BRAFV600 mutant melanoma: Anti-PD-1 before and after BRAF inhibition. J Immunother 2017;40(1):31-5. Abstract

Larkin J et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019;381(16):1535-46. Abstract

Larkin J et al. Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067). AACR 2017;Abstract CT075.

Lebbe C et al. Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). ESMO 2018;Abstract LBA47.

Luke JJ. Comprehensive clinical trial data summation for BRAF-MEK inhibition and checkpoint immunotherapy in metastatic melanoma. Oncologist 2019;24(11):e1197-e1211. Abstract

McArthur G et al. Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial. AACR 2020;Abstract CT012.

Olson D et al. Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial. ASCO 2020;Abstract 10004.

Pires Da Silva I et al. Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI + PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. ASCO 2020;Abstract 10005.

Postow MA et al. A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy. ASCO 2020;Abstract 10003.

Robert C et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019;381(7):626-36. Abstract

Robert C et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 2019;20(9):1239-51. Abstract

Van den Heuvel NMJ et al. Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only, compared to therapeutic lymph node dissection: First results of the PRADO trial. ASCO 2020;Abstract 10064.

Zimmer L et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;395(10236):1558-68. Abstract